New antibiotic, Xenleta, receives FDA approval to treat community-acquired bacterial pneumonia

The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. "This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease," said Ed Cox, M.D., M.P.H., director of FDA's Office of Antimicrobial Products. "For managing this serious disease, it is important ["]

The post New antibiotic, Xenleta, receives FDA approval to treat community-acquired bacterial pneumonia appeared first on Outbreak News Today.